|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2010-11-16
|
|
pubmed:abstractText |
In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5371-3
|
|
pubmed:meshHeading |
pubmed-meshheading:21062927-Antineoplastic Agents,
pubmed-meshheading:21062927-Disease Progression,
pubmed-meshheading:21062927-Drug Resistance, Neoplasm,
pubmed-meshheading:21062927-Humans,
pubmed-meshheading:21062927-Lung Neoplasms,
pubmed-meshheading:21062927-Molecular Targeted Therapy,
pubmed-meshheading:21062927-Mutation,
pubmed-meshheading:21062927-Protein Kinase Inhibitors,
pubmed-meshheading:21062927-Receptor, Epidermal Growth Factor
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer.
|
|
pubmed:affiliation |
Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
|
|
pubmed:publicationType |
Journal Article
|
